Arbutus to Announce Q3 2024 Financial Results and Corporate Update

Arbutus Biopharma Corporation, a clinical-stage biopharmaceutical firm with a focus on virology, has set a schedule for releasing its financial results for the third quarter of 2024. The company aims to develop a functional cure for chronic hepatitis B virus (cHBV) infection. The financial results and corporate update will be announced on Wednesday, November 6, 2024. The press release will be issued at 7:30 a.m. Eastern Time (ET), followed by a conference call and webcast at 8:45 a.m. ET the same day. Interested parties can register for the conference call through a provided link, and a live webcast will be available on the Arbutus website. For those unable to attend the live session, an archived version will be accessible on the company's website afterward.

Arbutus Biopharma, listed on Nasdaq under the ticker ABUS, is engaged in the development of innovative therapies with unique mechanisms of action to combat cHBV. The company's strategic approach focuses on suppressing HBV DNA, diminishing surface antigen, and enhancing HBV-specific immune responses. Their pipeline includes imdusiran (AB-729), an RNAi therapeutic, and AB-101, an oral PD-L1 inhibitor.

Imdusiran has produced significant clinical data showing its ability to reduce surface antigen levels and stimulate HBV-specific immune responses. This drug is currently undergoing two Phase 2a combination clinical trials. Meanwhile, AB-101 is in the midst of a Phase 1a/1b clinical trial. Arbutus believes that combining these novel therapeutics could lead to a functional cure for HBV patients.

Arbutus' mission is driven by its extensive knowledge in virology and dedication to discovering treatments that can provide lasting benefits for individuals affected by hepatitis B. For further details about their research and development efforts, updates on clinical trials, and other corporate information, one can visit their official website.